HealthEdge Investment Partners (HealthEdge) has completed the final close of its fourth fund, HealthEdge Investment Fund IV, (Fund IV), above its original target with over $160 million of capital commitments, including an investment from the General Partner.
The fund also attracted support from HealthEdge’s existing limited partner base, including funds of funds, pension funds, endowments, and high-net-worth individuals.
Fund IV will pursue the same investment strategy of its three predecessor funds by providing the first institutional capital to entrepreneurial businesses in “attractive segments” of the healthcare industry.
To date, Fund IV has allocated approximately 24% of its capital to its first two platform investments: Anodyne, a leading provider of clinical footwear solutions for the growing diabetic population, and Veridian Healthcare, an outsourced manufacturer and distributor of private label and branded in-home diagnostic, pain care management, and personal care products.
Since 2006, HealthEdge has completed 70 acquisitions, including 21 platforms and 49 add-ons, and 13 exits, while expanding the HealthEdge team to 17 people, including eight investment professionals.
Touchstone acted as the exclusive placement agent to Fund IV. Hill Ward Henderson, LLP served as legal counsel.
